When was BluSense Diagnostics founded?

BluSense Diagnostics was founded in 2014 and raised its 1st funding round within a year of its incorporation.

Where is BluSense Diagnostics located?

BluSense Diagnostics is headquartered in Copenhagen, Denmark. It is registered at Fruebjergvej 3.

Who is the current CEO of BluSense Diagnostics?

Filippo Bosco of BluSense Diagnostics.

Which legal entities is BluSense Diagnostics associated with?

BluSense Diagnostics is associated with Blusense Diagnostics ApS.

How many employees does BluSense Diagnostics have?

As of Apr 30, 2026, the latest employee count at BluSense Diagnostics is 10.

Is BluSense Diagnostics a funded company?

BluSense Diagnostics is a funded company, having raised a total of $14.1M across 13 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on 2014.

When was the latest funding round of BluSense Diagnostics?

BluSense Diagnostics' latest funding was a $***** Series B round on Feb 03, 2020, with participation from 0 investor.

Where does BluSense Diagnostics rank among its competitors?

BluSense Diagnostics ranks 44th amongst 170 active competitors, of which 50 are funded. It stands 8th in terms of total funding among its competitors. The most recent competitor to raise funding was HaystackAnalytics, which secured $5M in Sep, 2025.

Who are the top competitors of BluSense Diagnostics?

BluSense Diagnostics' top competitors include OpGen, HaystackAnalytics and Souzhou Ribo Life Science. Among them, HaystackAnalytics secured the most recent funding round in September, 2025.

BluSense Diagnostics - 2026 Company Profile, Team, Funding, Competitors & Financials

BluSense Diagnostics is a deadpooled company based in Copenhagen (Denmark), founded in 2014 by Robert Burger and Filippo Bosco. It operates as a Developer of a next-generation diagnostics platform to diagnose infectious diseases. BluSense Diagnostics has raised $14.1M in funding, with last known valuation of $*****. The company has 170 active competitors, including 50 funded and 27 that have exited. Its top competitors include companies like OpGen, HaystackAnalytics and Souzhou Ribo Life Science.

Company Details

Developer of a next-generation diagnostics platform to diagnose infectious diseases. The product includes BluBox which is a portable IVD device for single-drop-of-blood diagnostics for dengue and the COVID-19 and another device ViroTrack for virus identification. It is based on centrifugal microfluidics technology, magnetic nanoparticle physics, and Blu-Ray optics.

Website: www.blusense-diagnostics.com/en
Social
Registered Address: Fruebjergvej 3

Key Metrics

Founded Year

2014

Location

Copenhagen, Denmark

Stage

Deadpooled

Total Funding

$14.1M in 13 rounds

Latest Funding Round

Series B, Feb 03, 2020, $*****

Last Known Valuation

$***** as on May 08, 2018

Investors

Quanta Computer & 7 more

Ranked

44^th among 170 active competitors

Employee Count

10 as on Apr 30, 2026

Similar Companies

OpGen & 219 more

View BluSense Diagnostics' full profile

BluSense Diagnostics is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Blusense Diagnostics ApS CIN: DK36059184 , Denmark, Active	Jul 31, 2014	-	35 (As on Dec 31, 2021)

BluSense Diagnostics has raised a total funding of $14.1M over 13 rounds. Its first funding round was on 2014. BluSense Diagnostics has 8 institutional investors.

Here is the list of recent funding rounds of BluSense Diagnostics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Feb 03, 2020	9189140	Series B	6617613	2735662	1790124	2641924
Jan 01, 2020	2306396	Grant (prize money)	8911868	6859541	8118775	Europa
Jan 01, 2019	6924374	Grant (prize money)	1302541	4660058	4937492	Europa

Access funding benchmarks and valuations. Sign up today!

View details of BluSense Diagnostics's funding rounds and investors

The founders of BluSense Diagnostics are Robert Burger and Filippo Bosco.

Here are the details of BluSense Diagnostics' key team members:

Robert Burger: COO & Founder of BluSense Diagnostics and founder of 1 other company. They serve on the board of 1 company.
Filippo Bosco: CEO & Founder of BluSense Diagnostics and founder of 1 other company.

BluSense Diagnostics' Board of Directors

BluSense Diagnostics's board has 7 active members. Robert Burger is part of team and Chen Yan, Leif Helth Jensen, Hans-joachim Maria Diedenhofen, Wei-chin Lee, Georgios Zachopoulos and Wei-lin Wang are independent board members.

Here is the list of BluSense Diagnostics' board of directors:

Name	Type	Representing	Status	Duration
bpyuofk	Team	-	Past	5y 7m
Chen Yan	Independent board member	-	Current	5y 7m
xzfuear	Independent board member	-	Current	8y 9m
{xewzec	Independent board member	-	Current	5y 1m
hribamk	Independent board member	-	Current	4y 8m
deilxfz	Independent board member	-	Current	8y 8m
nbxbdcv	Independent board member	-	Past	3y 2m

View details of BluSense Diagnostics's Founder profiles and Board Members

BluSense Diagnostics' employee count trend

BluSense Diagnostics has 10 employees as of Apr 26. Here is BluSense Diagnostics's employee count trend over the years:

Employee count trend for BluSense Diagnostics

Uncover BluSense Diagnostics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of BluSense Diagnostics include OpGen, HaystackAnalytics and Souzhou Ribo Life Science. Here is the list of Top 10 competitors of BluSense Diagnostics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	OpGen 2002, Rockville (United States), Public	Developer of diagnostics and bioinformatics platforms for providers	$77.5M	Cross Creek, 180 Degree Capital & 12 others	67/100
2nd	HaystackAnalytics 2018, Mumbai (India), Seed	Provider of genomics technology for personalized clinical decisions	$17.3M	STRIVE, Sun Pharma & 32 others	67/100
3rd	Souzhou Ribo Life Science 2007, Suzhou (China), Public	Developer of nucleic acid drugs based on RNA interference (RNAi) technology	$201M	Panlin Capital, Legend Capital & 13 others	60/100
4th	Karius 2014, Redwood City (United States), Series C	Provider of diagnostics for identifying infectious diseases using microbial DNA	$315M	Khosla Ventures, Gilde Healthcare & 16 others	58/100
5th	PathoQuest 2010, Paris (France), Acquired	Provider of next-generation sequencing for microbiology testing	$9.99M	Kurma Partners, Charles River Laboratories ... & 9 others	57/100
6th	Clear Labs 2014, Menlo Park (United States), Series D	Provider of food safety technologies for the identification of pathogens	$171M	Menlo Ventures, Google Ventures & 26 others	57/100
7th	Seegene Technologies 2000, Seoul (South Korea), Public	Provider of advanced molecular diagnostics solutions	-	IMM Investment, Songhyun Investment & 3 others	57/100
8th	Delve Bio 2022, San Francisco (United States), Series A	Developer of sequencing platform to detect neuro-infectious pathogens	$35M	Xontogeny, Google Ventures & 1 others	52/100
9th	OraSure 1987, Bethlehem (United States), Public	Provider of point-of-care diagnostic devices for oral fluid specimens	-	Public Health Emergency, Gates & 4 others	51/100
10th	Spring Bank Pharmaceuticals 2002, Milford (United States), Public	Developer of products to treat viral infections using its small molecule nucleic acid hybrid chemistry platform	$41.5M	NIH, HHS & 1 others	51/100
44th	BluSense Diagnostics 2014, Copenhagen (Denmark), Deadpooled	Developer of a next-generation diagnostics platform to diagnose infectious diseases	$14.1M	Quanta Computer, Taian Biotechnology & 6 others	38/100